


Technology: Insulin glargine is a long-acting recombinant human insulin analog that helps to control blood sugar levels in patients with diabetes.







Spotlight On: Insulin Glargine

VENABLE ...P

March 31, 2024

	Sanofi v. Eli Lilly 1:14-cv- 00113 (D. Del.) Settled	Sanofi v. Eli Lilly 1:14-cv- 00884 (D. Del.) Settled	Sanofi v. Merck 1:16-cv- 00812 (D. Del.) Stipulated dismissal	Sanofi v. Merck 2:17-cv- 05914 (D.N.J.) Stipulated dismissal	Sanofi v. Mylan 2:17-cv- 09105 (D.N.J.) Claims not infringed, but invalid Appeal 21- 1262 Dismissed as Moot	Mylan v. Sanofi IPR2017-01526 FWD (All instituted claims unpatentable); Appeal 19-1368 Affirmed, Rehearing denied; Sup. Ct. 19-1451 Cert Denied	Mylan v. Sanofi IPR2017-01528 FWD (All instituted claims unpatentable); Appeal 19-1369 Affirmed, Rehearing denied; Sup. Ct. 19-1451 Cert Denied	Mylan v. Sanofi IPR2018-01670 FWD (Instituted claim unpatentable) Appeal 20-1871 Pending <i>Pfizer v. Sanofi</i> IPR2019-00979 (Joinder denied) FWD (All instituted claims unpatentable); Appeal 20-2159 Affirmed	Mylan v. Sanofi IPR2018-01675 IPR2018-01676 Pfizer v. Sanofi IPR2019-00977 IPR2019-00978 Joined FWD (All instituted claims unpatentable); Appeals 20-2029 Dismissed as Moot, 20- 2032 Affirmed	Mylan v. Sanofi IPR2018-01677 Terminated prior to institution decision; Refiled as IPR2019- 00122, <i>Pfizer v. Sanofi</i> IPR2019-00982 Joined FWD (All instituted claims unpatentable); Appeal 20-2034 Dismissed as Moot	Mylan v. Sanofi IPR2018-01678 IPR2018-01679 Pfizer v. Sanofi IPR2019-00980 IPR2019-00981 Joined FWD (All instituted claims unpatentable); Appeals 20-2033, 20- 2066 Affirmed
7,476,652	x	x	X	X	x	x					
7,713,930	x	x	x	x	x		x				
7,918,833		x	x		x						
8,512,297		x	x		x						
8,556,864	x	x	x		x						
8,603,044	x	x	x		x				x		
8,679,069	x	x	x		x			x			
8,992,486			x		x					x	x
9,011,391			x		x				Mylan v. Sanofi		Mylan v. Sanofi
9,233,211			x		x		Mylan v. Sanofi IPR2019- 01658 Institution denied	<i>Mylan v. Sanofi</i> IPR2019-01657 FWD (All instituted claims unpatentable); Appeal 21-1981 Reversed	IPR2018-01680 IPR2018-01682 <i>Pfizer v. Sanofi</i> IPR2019-01022 IPR2019-01023 Joined FWD (All instituted claims unpatentable); Appeals 20-2068 Affirmed, 20-2069 Dismissed as Moot	<i>Mylan v. Sanofi</i> IPR2018-01696 Institution denied	IPR2018-01684 Pfizer v. Sanofi IPR2019-00987 Joined FWD (Some instituted claims unpatentable); Appeal 20-2071 Affirmed, 20-2139 & 20-2144 Withdrawn
9,408,979					x						
9,457,152			x								
9,486,587			x								
9,526,844			x		x				x	x	
9,533,105			x		x						
9,561,331					x						
9,592,348			x								
9,604,008			x		x						x
9,604,009					x						
9,610,409					x						
9,623,189					x						
RE47,614							x	x			

